MX388518B - Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2. - Google Patents

Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.

Info

Publication number
MX388518B
MX388518B MX2019000837A MX2019000837A MX388518B MX 388518 B MX388518 B MX 388518B MX 2019000837 A MX2019000837 A MX 2019000837A MX 2019000837 A MX2019000837 A MX 2019000837A MX 388518 B MX388518 B MX 388518B
Authority
MX
Mexico
Prior art keywords
inhibitors
aminopyridine derivatives
compound
selective alk
alk
Prior art date
Application number
MX2019000837A
Other languages
English (en)
Other versions
MX2019000837A (es
Inventor
Dimitrios Lizos
Jialiang Li
Jianwei Bian
Kai Cui
Liladhar Murlidhar Waykole
Luca Arista
Lv Liao
Michael Patrick Dillon
Nikolaus Johannes Stiefl
Peggy Usselmann
Rene Lattmann
Rita Ramos
Sreehari Babu
Sven Weiler
Thomas Ullrich
Tingying Zhu
Xiaoyang Wang
Yizong Zhou
Yubo Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019000837A publication Critical patent/MX2019000837A/es
Publication of MX388518B publication Critical patent/MX388518B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable (I), a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de osificación heterotópica y fibrodisplasia osificante progresiva. (Ver Fórmula).
MX2019000837A 2016-07-20 2017-07-18 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2. MX388518B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (2)

Publication Number Publication Date
MX2019000837A MX2019000837A (es) 2019-07-04
MX388518B true MX388518B (es) 2025-03-19

Family

ID=60991950

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000837A MX388518B (es) 2016-07-20 2017-07-18 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
MX2021014852A MX2021014852A (es) 2016-07-20 2019-01-18 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014852A MX2021014852A (es) 2016-07-20 2019-01-18 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.

Country Status (25)

Country Link
US (3) US10710980B2 (es)
EP (3) EP3971177B1 (es)
JP (4) JP7030776B2 (es)
KR (7) KR102719881B1 (es)
CN (2) CN114014844B (es)
AR (1) AR109108A1 (es)
AU (5) AU2017298187B2 (es)
CY (1) CY1124967T1 (es)
DK (2) DK3487851T3 (es)
EA (2) EA037520B1 (es)
ES (2) ES2902521T3 (es)
FI (1) FI3971177T3 (es)
HR (2) HRP20211868T1 (es)
HU (2) HUE067992T2 (es)
LT (2) LT3971177T (es)
MX (2) MX388518B (es)
PL (2) PL3971177T3 (es)
PT (2) PT3971177T (es)
RS (2) RS62819B1 (es)
RU (1) RU2747318C2 (es)
SI (2) SI3487851T1 (es)
SM (2) SMT202100723T1 (es)
TW (5) TWI755255B (es)
UY (1) UY37331A (es)
WO (1) WO2018014829A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3971177T (pt) 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
WO2021102258A1 (en) * 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
CN115968289B (zh) * 2020-06-16 2025-09-30 因赛特公司 用于治疗贫血的alk2抑制剂
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
KR950704485A (ko) 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2521766A1 (en) 2003-04-11 2004-10-28 Sgx Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
EA200601982A1 (ru) 2004-05-27 2007-04-27 Пфайзер Инк. Производные аминопиридина в качестве селективных агонистов d3 - дофаминовых рецепторов
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
BRPI0607913A2 (pt) 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd agente terapÊutico para discinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
WO2007123896A2 (en) 2006-04-18 2007-11-01 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
WO2008002671A2 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
WO2008033408A2 (en) 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
US20110294836A1 (en) 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
KR101630501B1 (ko) 2010-08-20 2016-06-15 와이어쓰 엘엘씨 디자이너 골형성 단백질
CN103402520A (zh) 2010-12-06 2013-11-20 皮拉马尔企业有限公司 具有取代基的咪唑并喹啉衍生物
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012161877A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
CN104159890B (zh) 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CA2886187C (en) * 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
JP2016510745A (ja) * 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
JP6433974B2 (ja) * 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
EP3060550B1 (en) 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
MX387785B (es) 2015-08-31 2025-03-18 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos.
JP7030775B2 (ja) 2016-07-20 2022-03-07 キャベンディッシュ・キネティックス・インコーポレイテッド Ｄｖｃを用いてアンテナを調整する方法
PT3971177T (pt) * 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
FI3971177T3 (fi) 2024-07-30
AU2019246857A1 (en) 2019-10-31
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
PL3971177T3 (pl) 2024-10-28
RU2019104609A (ru) 2020-08-20
RU2021111037A (ru) 2021-05-13
WO2018014829A1 (en) 2018-01-25
US20200299265A1 (en) 2020-09-24
PL3487851T3 (pl) 2022-04-11
HUE067992T2 (hu) 2024-12-28
EP3487851A4 (en) 2019-12-25
KR20240074904A (ko) 2024-05-28
TW202509017A (zh) 2025-03-01
KR20230117248A (ko) 2023-08-07
RS66041B1 (sr) 2024-11-29
ES2984746T3 (es) 2024-10-30
CA3030332A1 (en) 2018-01-25
JP2022078137A (ja) 2022-05-24
HRP20241015T1 (hr) 2024-11-08
HRP20211868T1 (hr) 2022-03-04
AU2024205058A1 (en) 2024-08-15
SI3487851T1 (sl) 2022-03-31
SMT202100723T1 (it) 2022-01-10
CN114014844B (zh) 2024-10-01
KR20240155367A (ko) 2024-10-28
CY1124967T1 (el) 2023-01-05
TWI851226B (zh) 2024-08-01
AU2017298187A1 (en) 2018-12-20
MX2019000837A (es) 2019-07-04
AU2023200265A1 (en) 2023-02-16
RU2747318C2 (ru) 2021-05-04
DK3487851T3 (da) 2021-12-20
EP4442317A3 (en) 2025-01-01
SMT202400335T1 (it) 2024-09-16
ES2902521T3 (es) 2022-03-28
KR102719881B1 (ko) 2024-10-23
AU2021201424A1 (en) 2021-03-25
MX2021014852A (es) 2022-01-18
US20190161474A1 (en) 2019-05-30
HUE057328T2 (hu) 2022-05-28
EA037520B1 (ru) 2021-04-07
RU2019104609A3 (es) 2020-09-30
TWI712598B (zh) 2020-12-11
KR20210094138A (ko) 2021-07-28
RU2021111037A3 (es) 2022-02-10
US20210155606A1 (en) 2021-05-27
JP7030776B2 (ja) 2022-03-07
AU2019246857B2 (en) 2020-12-24
AU2023200265B2 (en) 2024-08-15
EA202190285A1 (ru) 2021-08-31
SI3971177T1 (sl) 2024-10-30
JP2023089012A (ja) 2023-06-27
KR102281550B1 (ko) 2021-07-27
PT3487851T (pt) 2022-01-07
CN114014844A (zh) 2022-02-08
TW202220969A (zh) 2022-06-01
DK3971177T3 (da) 2024-07-15
JP7253086B2 (ja) 2023-04-05
JP2025032086A (ja) 2025-03-11
TW201805277A (zh) 2018-02-16
EP3971177A1 (en) 2022-03-23
EP3971177B1 (en) 2024-06-26
EP4442317A2 (en) 2024-10-09
TWI806385B (zh) 2023-06-21
RS62819B1 (sr) 2022-02-28
JP7584553B2 (ja) 2024-11-15
KR102359707B1 (ko) 2022-02-09
AR109108A1 (es) 2018-10-31
EP3487851B1 (en) 2021-10-20
KR102454129B1 (ko) 2022-10-14
LT3487851T (lt) 2021-12-27
EP3487851A1 (en) 2019-05-29
TW202336011A (zh) 2023-09-16
KR102667331B1 (ko) 2024-05-21
TW202134228A (zh) 2021-09-16
LT3971177T (lt) 2024-08-26
US12466808B2 (en) 2025-11-11
UY37331A (es) 2018-02-28
PT3971177T (pt) 2024-07-30
US10710980B2 (en) 2020-07-14
EA201990343A1 (ru) 2019-06-28
BR112019000941A2 (pt) 2019-04-30
KR20220143770A (ko) 2022-10-25
JP2019521167A (ja) 2019-07-25
CN109641871A (zh) 2019-04-16
AU2021201424B2 (en) 2022-10-20
KR102559539B1 (ko) 2023-07-26
US10947218B2 (en) 2021-03-16
TWI755255B (zh) 2022-02-11
KR20190026917A (ko) 2019-03-13
CN109641871B (zh) 2021-10-22
KR20220021023A (ko) 2022-02-21

Similar Documents

Publication Publication Date Title
MX388518B (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
MX2020011774A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
CR20190156A (es) Derivados de bipirazol como inhibidores jak
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX388750B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
CY1122196T1 (el) Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
PE20160689A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
MX372740B (es) Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
JOP20200030A1 (ar) مركب خماسي الحلقة
CY1121624T1 (el) Παραγωγα 2-αρυλο-4-υδροξυ-1,3-θειαζολιου χρησιμα ως αναστολεις trpm8 για τη θεραπεια της νευραλγιας, του πονου, της χαπ και του ασθματος
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
EA201791596A1 (ru) Пиразоловые соединения